stockrowLakefront Biotherapeutics - Sponsored ADR
LKFT Healthcare Biotechnology
Lakefront Biotherapeutics - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $1.3 billion, up 321.9% from fiscal 2024.
- Revenue
- −95.4%
- EPS
- +198.9%
- Free cash flow
- +18.2%
Quarter to June 2026, against a year earlier
Follow LKFT
Alert me
Lakefront Biotherapeutics - Sponsored ADR (LKFT) Net income
Lakefront Biotherapeutics - Sponsored ADR's net income for fiscal 2025 was $363.0M, up 352.9% from $80.2M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$652.4M. Over the past ten years it has ranged from −$348.9M (fiscal 2020) to $363.0M (fiscal 2025) — the current reading is the highest in ten years. Lakefront Biotherapeutics - Sponsored ADR ranks 596th of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $363.0M | 352.88% |
| FY2024 | $80.2M | (65.01%) |
| FY2023 | $229.1M | — |
| FY2022 | −$229.7M | — |
| FY2021 | −$122.1M | — |
| FY2020 | −$348.9M | — |
| FY2019 | $167.8M | — |
| FY2018 | −$34.6M | — |
| FY2017 | −$130.8M | — |
| FY2016 | $59.8M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | $2.3M | (86.20%) |
| Mar 2026 | $17.0M | — |
| Sep 2025 | −$539.2M | — |
| Jun 2025 | −$132.6M | — |
| 34 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| AUPH Aurinia Pharmaceuticals Inc compare | $314.3M |
| VCEL Vericel Corporation compare | $33.3M |
| SEPN Septerna, Inc. compare | −$24.2M |
| PVLA Palvella Therapeutics, Inc. compare | −$61.7M |
| ZYME Zymeworks Inc. compare | −$150.0M |
| IMNM Immunome, Inc. compare | −$254.3M |
| VERA Vera Therapeutics, Inc. compare | −$401.9M |
| BHVN Biohaven Ltd. compare | −$542.7M |
| LKFT Lakefront Biotherapeutics - Sponsored ADR | −$652.4M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on LKFT
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement